In contrast, anti-PD-L1 checkpoint blockade therapy for PC patients is not predicted to be significantly beneficial where tumours have altered TP53, and particularly not for patients with advanced disease stage, where PD-L1 levels are predicted to be universally low. The gene discussed is TP53; the disease is pachyonychia congenita.